{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:14:29Z","timestamp":1789146869491,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020910","name":"Pierre Fabre Research Institute Boulogne-Billancourt","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020910","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Les Laboratories Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.lungcan.2026.109580","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:08:26Z","timestamp":1786633706000},"page":"109580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study"],"prefix":"10.1016","volume":"220","author":[{"given":"Huaqiang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qisen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuh-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenza","family":"Bouras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence Del","family":"Frari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Klauck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Sansas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109580_b0005","unstructured":"International Agency for Research on Cancer, Globocan 2022. Website. https:\/\/gco.iarc.fr\/today\/en\/dataviz\/tables?mode=cancer&group_populations=1&multiple_populations=1&cancers=39&populations=160&sort_by=value0."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109580_b0010","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","article-title":"Oncogenic driver mutations in non-small cell lung cancer: past, present and future","volume":"12","author":"Chevallier","year":"2021","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109580_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105652","article-title":"Prevalence, genetic variations and clinical outcomes of BRAF-V600 mutated advanced NSCLC in China: a retrospective real-world multi-centre study","volume":"114","author":"Jia","year":"2025","journal-title":"EBioMedicine"},{"issue":"Suppl 1","key":"10.1016\/j.lungcan.2026.109580_b0020","article-title":"BRAF in non-small cell lung cancer: From molecular mechanisms to clinical practice","volume":"131","author":"Parisi","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2026.109580_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1141876","article-title":"Therapeutic strategies for BRAF mutation in non-small cell lung cancer: a review","volume":"13","author":"Puri","year":"2023","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109580_b0030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/cam4.1014","article-title":"Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation","volume":"6","author":"Ding","year":"2017","journal-title":"Cancer Med"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109580_b0035","first-page":"1145","article-title":"Advances in the treatment of BRAF V600-mutant non-small cell lung cancer","volume":"31","author":"Zhao","year":"2021","journal-title":"China Oncol"},{"issue":"12","key":"10.1016\/j.lungcan.2026.109580_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103996","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer","volume":"9","author":"Lee","year":"2024","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109580_b0045","first-page":"77","article-title":"Updates to the 2024 CSCO advanced non-small cell lung cancer guidelines","volume":"22","author":"Wang","year":"2025","journal-title":"Cancer Biol Med"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109580_b0050","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.annonc.2025.06.007","article-title":"ESMO Guidelines Committee, Updated treatment recommendations for systemic treatment: from the ESMO oncogene-addicted metastatic NSCLC living guideline","volume":"36","author":"Hendriks","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109580_b0055","doi-asserted-by":"crossref","unstructured":"G.J. Riely, D.E. Wood, D.S. Ettinger, D.L. Aisner, W. Akerley, J.R. Bauman, A. Bharat, D.S. Bruno, J.Y. Chang, L.R. Chirieac, M. DeCamp, A.P. Desai, T.J. Dilling, J. Dowell, G.A. Durm, S. Gettinger, T.E. Grotz, M.A. Gubens, A. Juloori, R.P. Lackner, M. Lanuti, J. Lin, B.W. Loo, C.M. Lovly, F. Maldonado, E. Massarelli, D. Morgensztern, T.C. Mullikin, T. Ng, D. Owen, D.H. Owen, S.P. Patel, T. Patil, P.M. Polanco, J. Riess, T.A. Shapiro, A.P. Singh, J. Stevenson, A. Tam, T. Tanvetyanon, J. Yanagawa, S.C. Yang, E. Yau, K.M. Gregory, L. Hang, Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology, J. Natl. Compr. Canc. Netw. 22(4) (2024) 249-274.","DOI":"10.6004\/jnccn.2204.0023"},{"issue":"10","key":"10.1016\/j.lungcan.2026.109580_b0060","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jtho.2025.05.023","article-title":"Updated efficacy and safety from the phase 2 PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC-A brief report","volume":"20","author":"Riely","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2026.109580_b0065","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1200\/JCO.23.00774","article-title":"Phase II, open-label study of encorafenib plus binimetinib in patients with BRAF(V600)-mutant metastatic non-small-cell lung cancer","volume":"41","author":"Riely","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"35","key":"10.1016\/j.lungcan.2026.109580_b0070","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1200\/JCO-25-02023","article-title":"Updated overall survival analysis from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer","volume":"43","author":"Johnson","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109580_b0075","unstructured":"European Medicines Agency, Braftovi. Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/braftovi-epar-product-information_en.pdf (accessed 28 January 2026), (2025)."},{"key":"10.1016\/j.lungcan.2026.109580_b0080","unstructured":"US Food & Drug Administration, Braftovi. Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/210496s017lbl.pdf (accessed 2 February 2026)."},{"key":"10.1016\/j.lungcan.2026.109580_b0085","unstructured":"European Medicines Agency, Mektovi. Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/mektovi-epar-product-information_en.pdf (accessed 24 April 2026)."},{"key":"10.1016\/j.lungcan.2026.109580_b0090","unstructured":"United States Food and Drug Administration, Mektovi. Prescribing Information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210498lbl.pdf (accessed 24 April 2026)."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109580_b0095","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5732\/cjc.011.10106","article-title":"East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians","volume":"30","author":"Zhou","year":"2011","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109580_b0100","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fonc.2020.00603","article-title":"Clinical characteristics and treatment outcomes of 65 patients with BRAF-mutated non-small cell lung cancer","volume":"10","author":"Mu","year":"2020","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109580_b0105","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.21037\/tlcr-24-494","article-title":"Efficacy, safety, and quality of life of dabrafenib plus trametinib treatment in Chinese patients with BRAF (V600E) mutation-positive metastatic non-small cell lung cancer","volume":"13","author":"Fan","year":"2024","journal-title":"Transl Lung Cancer Res"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109580_b0110","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1007\/s12325-024-03069-4","article-title":"First-line pembrolizumab plus chemotherapy for HER2-negative advanced gastric cancer: china subgroup analysis of the randomized phase 3 KEYNOTE-859 study","volume":"42","author":"Qin","year":"2025","journal-title":"Adv. Ther."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109580_b0115","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2026.109580_b0120","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejca.2019.07.016","article-title":"Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management","volume":"119","author":"Gogas","year":"2019","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109580_b0125","first-page":"467","article-title":"A phase 2 study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan","volume":"34","author":"Tahara","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.lungcan.2026.109580_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114073","article-title":"COLUMBUS 7-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E\/K-mutant melanoma","volume":"204","author":"Schadendorf","year":"2024","journal-title":"Eur. J. Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006410?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226006410?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:53:24Z","timestamp":1789145604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226006410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":26,"alternative-id":["S0169500226006410"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109580","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAFV600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109580"}}